Altre lingue Stayble Therapeutics AB

Azioni

STABL

SE0013513652

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 18:00:00 10/06/2024			Variaz. 5gg	Var. 1 gen.
0,264 ^SEK	-0,75%		+4,35%	-12,87%

21/05	Stayble Therapeutics AB (publ) riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
20/02	Stayble Therapeutics AB (publ) riporta i risultati degli utili per il quarto trimestre e l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Stayble Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	21/05
Stayble Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	20/02
Stayble's CEO to BioStock: "We are looking forward to new study results in 2024"	12/01
BioStock: Stayble's new analyses of phase IIb study strengthen disc herniation project	18/12
Stayble Therapeutics Announces New Analyses of Phase IIb Study Strengthen Disc Herniation Project	18/12
BioStock: Stayble Therapeutics shifts focus to phase Ib study in disc herniation	22/11
Stayble Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
BioStock: Stayble did not reach the primary endpoint in phase IIb	09/11
BioStock: Stayble Therapeutics presents phase IIb data within one month	03/11
Toleranzia Appoints Successor to Outgoing CFO	16/10/23
BioStock: Stayble reports last patient last visit in the phase IIb study	14/09/23
Stayble Therapeutics Terminates Liquidity Provider Agreement	06/09/23
BioStock: Stayble enrols the first patient in herniated disc study	04/09/23
Stayble Enters the First Patient in Herniated Disc Study	04/09/23
Stayable Therapeutics Enrols First Patient for Herniated Discs Trial	28/08/23
BioStock: Progress for Stayble Therapeutics in the second quarter	25/08/23
Stayble Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	22/08/23
Certain Shares of Stayble Therapeutics AB are subject to a Lock-Up Agreement Ending on 22-AUG-2023.	22/08/23
BioStock: Stayble's phase IIb study nears the finishing line	24/07/23
Stayble Therapeutics Phase IIb Study Nears the Final Line	24/07/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Stayble Therapeutics AB

Azioni

STABL

SE0013513652

Altre lingue

Filtri